Covance: New offering applies Chiltern-developed engagement models

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Image Source)
(Image: Getty/Image Source)

Related tags Pharmacology Clinical trial

LabCorp’s Covance has launched a new dedicated offering for biotech, medical device, and diagnostic companies following its purchase of Chiltern in 2017.

These client segments have specific needs for their clinical trials, which can be different from those of larger biopharma companies​,” said Lewis Cameron, head of Global Clinical Development, Covance.

The offering applies “customized engagement models successfully developed by Chiltern​,” he told us.

Chiltern joined Covance, the drug development division of LabCorp, after being acquired in September 2017​ for $1.2bn.

The new dedicated offering, announced Monday, also provides access to additional resources provided by Covance and LabCorp, said Cameron, and includes access to the Covance MarketPlace, the company’s proprietary model for connecting biotech companies with co-development or investment partners.

Cameron explained the addition of Chiltern strengthened Covance’s “focus on the biotech client segment and deepened our therapeutic expertise, particularly in oncology​.”

“Chiltern also brought comprehensive capabilities in medical device development​,” he said, explaining that the company is “pleased​” with the progress of the Chiltern integration to date.

This offering demonstrates how we’re working to translate the powerful combination of Covance and Chiltern to benefit our clients​.”

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

Related suppliers

Follow us

Products

View more

Webinars